AXIS 2 Clinical Outcomes No Different Than Placebo

Buckley, Rita
April 2012
MD Conference Express;
The article focuses on the promising drug AX200 that fulfilled Stroke Therapy Academic Industry Roundtable (STAIR) and European Stroke Organization recommendations. It presents the results of Treatment of Ischemic Stroke Phase 3 trial by AX200 which shows no difference in clinical outcome or imaging compared with placebo in acute ischemic stroke patients.


Related Articles

  • Combined therapy with indapamide and perindopril but not peridopril alone reduced the risk for recurrent stroke. Tirschwell, David // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p51 

    Presents information on a study which compared the effectiveness of perindopril alone or combined with indapamide with placebo for reducing fatal or nonfatal stroke in patients with a history of stroke or transient ischemic attacks. Methodology of the study; Results; Comments on the study.

  • Acute stroke unit care and early neurological deterioration in ischemic stroke. Roquer, Jaume; Rodríguez-Campello, Ana; Gomis, Meritxell; Jiménez-Conde, Jordi; Cuadrado-Godia, Elisa; Vivanco, Rosa; Giralt, Eva; Sepúlveda, Maria; Pont-Sunyer, Claustre; Cucurella, Gracia; Ois, Angel // Journal of Neurology;Jul2008, Vol. 255 Issue 7, p1012 

    To evaluate the impact that monitored acute stroke unit care may have on the risk of early neurological deterioration (END), and 90-day mortality and mortality-disability. Non-randomized prospective study with consecutive patients with acute ischemic stroke (AIS) admitted to a conventional care...

  • VTE prophylaxis with enoxaparin demonstrated to be superior to unfractionated heparin in acute stroke patients.  // Formulary;Mar2007, Vol. 42 Issue 3, p192 

    The article discusses the characteristics of enoxaparin as superior to unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients with partial paralysis. Prophylaxis in acute ischemic stroke patients with restricted mobility has been recommended by 4...

  • The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada. Caro, J. Jaime; Migliaccio-Walle, Kristen; Ishak, Khajak J.; Proskorovsky, Irina; O'Brien, Judith A. // BMC Health Services Research;2006, Vol. 6, p99 

    Background: Documentation of the hospitalizations rates following a stroke provides the inputs required for planning health services and to evaluate the economic efficiency of any new therapies. Methods: Hospitalization rates by cause were examined using administrative data on 18,695 patients...

  • Recombinant Activated Factor VIIa: Phase III Trial Fails to Show Clinical Benefit. Segal, Alan Z. // Neurology Alert;Jul2008, Vol. 26 Issue 11, p86 

    RANDOMIZED STUDIES OF NEUROPROTECTIVE AGENTS for ischemic stroke have resulted in a series of failures, as multiple agents, promising in animal models, have failed when applied to human subjects. By contrast, intracerebral hemorrhage (ICH), has been somewhat a "neglected stepsister" when...

  • Rehabilitation.  // Current Medical Literature: Stroke Review;2006, Vol. 10 Issue 2, p63 

    The article discusses a study on follow-up therapy for persons with stroke in the U.S. The implementation of research for acute stroke care and rehabilitation is said to substantially reduce mortality rates. In addition, several disabled people with limited activity are living at home supported...

  • Be sure no eligible patient misses new treatment window for stroke.  // ED Nursing;Mar2010, Vol. 13 Issue 5, p49 

    You can increase the likelihood that your stroke patient will be eligible for treatment by identifying the time of symptom onset and performing interventions simultaneously. To improve care: • give patients a FAQ sheet to explain why they were ineligible for treatment; • suspect...

  • Alteplase cost saving following acute ischaemic stroke.  // PharmacoEconomics & Outcomes News;7/14/2007, Issue 532, p6 

    The article reports on the association of Alteplase with substantial cost savings for the treatment of acute ischemic strokes, according to a research from Canada. An estimated $Can678 cost savings per stroke patient is expected during the first poststroke year. About 20% of patients receiving...

  • Outcomes in Two Post-Acute Non-Inpatient Rehabilitation Settings. Rita Bode; Allen Heinemann; Donna Zahara; Linda Lovell // Topics in Stroke Rehabilitation;Jan2007, Vol. 14 Issue 1, p38 

    Background: Although several attempts have been made to look into the “black box” of inpatient rehabilitation, little is known about therapy effectiveness in outpatient settings. Method: This study described the characteristics of 167 persons with stroke referred to one of two...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics